ArticleCPT: pharmacometrics & systems pharmacology2021

Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.

Sergey Gavrilov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.